Share This Author
Human apolipoprotein A-IV. Intestinal origin and distribution in plasma.
- P. Green, R. Glickman, J. Riley, E. Quinet
- Biology, MedicineThe Journal of clinical investigation
- 1 April 1980
It is demonstrated that apoA-IV is present in human intestinal epithelial cells and is secreted as a chylomicron and VLDL apoprotein.
Gene-selective modulation by a synthetic oxysterol ligand of the liver X receptor Published, JLR Papers in Press, August 1, 2004. DOI 10.1194/jlr.M400257-JLR200
- E. Quinet, D. Savio, Anita R Halpern, Liang Chen, C. Miller, P. Nambi
- BiologyJournal of Lipid Research
- 1 October 2004
Cell-based studies indicate that DMHCA enhances cholesterol efflux in macrophages and suggest a mechanism whereby this selective modulator can potentially inhibit cholesterol accumulation, and may have application to the study and treatment of atherosclerosis.
Cholesteryl ester transfer protein and high density lipoprotein responses to cholesterol feeding in men: relationship to apolipoprotein E genotype.
ApoE genotype has significant and opposite effects on plasma CETP and HDL-C responses to dietary cholesterol in men.
Organization of the human cholesteryl ester transfer protein gene.
Comparison of the CETP sequence with sequence databases revealed a striking identity of a pentapeptide sequence (ValLeuThrLeuAla) within the hydrophobic core of the signal sequences of human CETP, apolipoproteins A-IV and A-I, and lipoprotein lipase, suggesting that it may mediate a specialized function related to lipid metabolism or transport.
Mechanism of cholesteryl ester transfer protein inhibition by a neutralizing monoclonal antibody and mapping of the monoclonal antibody epitope.
LXR ligand lowers LDL cholesterol in primates, is lipid neutral in hamster, and reduces atherosclerosis in mouse[S]
Way-252623 (LXR-623) is a highly selective and orally bioavailable synthetic modulator of LXR, which demonstrated efficacy for reducing lesion progression in the murine LDLR−/− atherosclerosis model with no associated increase in hepatic lipogenesis either in this model or Syrian hamsters.
Identification of phenylsulfone-substituted quinoxaline (WYE-672) as a tissue selective liver X-receptor (LXR) agonist.
Results suggest quinoxaline 13 may have an improved biological profile for potential use as a therapeutic agent and reduction of aortic arch lesion progression and no plasma or hepatic triglyceride increase are suggested.
Liver X Receptor (LXR)-β Regulation in LXRα-Deficient Mice: Implications for Therapeutic Targeting
Selective LXRβ activation is expected to stimulate ABCA1 gene expression in macrophages, contribute to favorable HDL increases, but circumvent hepatic LXRα-dominated lipogenesis.
Identification of 5α,6α-Epoxycholesterol as a Novel Modulator of Liver X Receptor Activity
- T. Berrodin, Q. Shen, E. Quinet, M. Yudt, L. Freedman, S. Nagpal
- Biology, ChemistryMolecular Pharmacology
- 1 December 2010
5,6-EC is the first dietary modulator and an endogenous LXR ligand with cell and gene context-dependent antagonist, agonist, and inverse agonist activities and is demonstrated to be one of the most potent natural LXRα ligands known to date.
Alternative splicing of the mRNA encoding the human cholesteryl ester transfer protein.
The experiments show that the expression of the human CETP gene is modified by alternative splicing of the ninth exon, in a tissue-specific fashion, which could serve to produce a protein with a function other than plasma neutral lipid transfer, or as an on-off switch to regulate the local concentration of biologically active protein.